These findings highlighted the specific molecular changes linked to tumor progression, such as increased expression of immunosuppressive genes galectin 1 (lgals1), triggering receptor expressed on myeloid cells 2 (trem2), as well as pathways related to extracellular ECM remodeling. The gene discussed is TREM2; the disease is neoplasm.